Editorials

Tumor Necrosis Factor Inhibition and Adipose Tissue Distribution — Are Reported Changes Relevant to Cardiometabolic Risk? B.J. Sheane ........................................ 1035

The TREAT Study — Trial or Tribulation? T.J.A. Lehman ......................................................... 1038

Reviews

Scleroderma Renal Crisis L. Mouthon, G. Bussone, A. Berezné, L-H. Noël, L. Guillemin ........................................ 1040


Articles

Discordance in Global Assessments Between Patient and Estimator in Patients with Newly Diagnosed RA: Associations with Progressive Joint Destruction and Functional Impairment Y. Kaneko, M. Kuwana, H. Kondo, T. Takeuchi ........................................ 1061

The Effect of Intravenous Golimumab on Health-related Quality of Life in RA: 24-week Results of the Phase III GO-FURTHER Trial C.O. Bingham III, M. Weinblatt, C. Han, et al ........................................ 1067

Longterm Safety, Efficacy, and Inhibition of Structural Damage Progression Over 5 Years of Treatment with Abatacept in Patients with RA in the Abatacept in Inadequate Responders to Methotrexate Trial J.M. Kremer, C. Peterfy, A.S. Russell, et al ........................................ 1077

Bone Marrow Edema on MRI of the Sacroiliac Joints Is Associated with Development of Fatty Lesions on MRI over a 1-year Interval in Patients with Early Inflammatory Low Back Pain: A 2-year Followup Study M. van Onna, A. van Tubergen, D.M. van der Heijde, A.G. Jurik, R. Landewé ........................................ 1088

The Effect of Golimumab Therapy on Disease Activity and Health-related Quality of Life in Patients with Ankylosing Spondylitis: 2-year Results of the GO-RAISE Trial D. van der Heijde, A. Deodhar, J. Braun, et al ........................................ 1095

Higher Expression of Whole Blood MicroRNA-21 in Patients with Ankylosing Spondylitis Associated with Programmed Cell Death 4 mRNA Expression and Collagen Cross-linked C-telopeptide Concentration C-H. Huang, J-C-C. Wei, W-C. Chang, et al ........................................ 1104

Early Increase of Abdominal Adiposity in Patients with Spondyloarthritis Receiving Anti-tumor Necrosis Factor-α Treatment I. Hmamouchi, C. Roux, S. Paternotte, S. Kolta, M. Dougados, K. Briot ........................................ 1112

Interleukin 18: A Biomarker for Differential Diagnosis Between Adult-onset Still’s Disease and Sepsis R. Priori, S. Colafrancesco, C. Alessandri, et al ........................................ 1118

Resistive Home Exercise in Patients with Recent-onset Polymyositis and Dermatomyositis — A Randomized Controlled Single-blinded Study with a 2-year Followup H. Alexanderson, L. Alemo Munters, M. Dastmalchi, et al ........................................ 1124

Arthritis in Idiopathic Inflammatory Myopathy: Clinical Features and Autoantibody Associations M. Klein, H. Mann, L. Pleštšilová, et al ........................................ 1133

Significance of Small Renal Artery Lesions in Patients with Antineutrophil Cytoplasmic Antibody-associated Glomerulonephritis A. Endo, J. Hoshino, T. Suwabe, et al ........................................ 1140


Development of Quality Indicators for an Integrated Approach of Knee OA L. Grypdonck, B. Aertgeerts, F. Luyten, et al ........................................ 1155

Pediatric Rheumatology

Clinically Inactive Disease in a Cohort of Children with New-onset Polyarticular JIA Treated with Early Aggressive Therapy: Time to Achievement, Total Duration, and Predictors C.A. Wallace, E.H. Giannini, S.J. Spalding, et al, for the Childhood Arthritis and Rheumatology Research Alliance (CARRA) ........................................ 1163

Discrepancy Between Clinical and Radiological Responses to Tocilizumab Treatment in Patients with Systemic-onset JIA C. Aoki, Y. Inaba, H. Choe, et al ........................................ 1171